Researchers Develop A New Nano Drug To Treat Triple Negative Breast Cancer

Researchers Develop A New Nano Drug To Treat Triple Negative Breast Cancer

Published: 08-Aug-2020 | Published By: Market Research Store

The University of Arkansas researchers have created a novel nano drug candidate that possesses the ability to destroy the triple negative breast cancer cells. In the world, triple negative breast cancer is found to be one of the lethal and aggressive types of breast cancer. Most of the deaths in women occur due to this type of breast cancer. However, the researchers hope that targeting these breast cancer cells directly will help inhibit any toxic or adverse effects of chemotherapy. This study has been published in Advanced Therapeutics. According to lead researcher Hassan Beyzavi, the linking of a new class of nanomaterials named metal-organic frameworks with ligands of a photodynamic therapy drug to form a nano-porous material will help target and kill tumor cells without harming the normal cells.

Metal-organic frameworks are a firsthand class of nanomaterials that have been developed for targeted drug delivery. Breast cancer is found to be affecting millions of women in the U.S. The death rate associated with triple negative breast cancer is found to be escalating and this is majorly due to the toxic effects of the approved drugs used to treat this cancer. Thus, it is the primary reason why the researchers developed a co-formulation to target the triple negative cancer cells without harming the healthy cells. Additionally, targeted photodynamic therapy drugs (PDT) are also being developed as an alternative to chemotherapy. PDT is a non-invasive approach that creates toxic reactive oxygen species to kill the cancer cells. No surgery and chemotherapy in case of PDT has helped it gather a lot of attention. The bio-conjugation of nanomaterials with PDT ligands helped create nanoporous materials that could be later used to destroy tumor cells.

Moreover, the idea of combining this novel drug delivery system with magnetic resonance imaging (MRI) or fluorescence imaging in the cancer treatment could aid in tracing the drug in the body plus monitor the evolution of cancer treatment. While the aggressive breast cancer cannot be treated with receptor-targeted therapy, chemotherapy, or surgeries owing to its rapid property of metastasizing cytotoxic chemotherapy is the only approved treatment for this type of breast cancer. And anthracyclines, such as doxorubicin, used for the treatment are found to have serious side effects and multi-drug resistance. Thus, the researchers find their study to be promising in treating triple negative breast cancer.

Market Research Store has published a report on global nano drug industry market. This report offers all the details regarding the characteristics and the entire history of the industrial development of the nano drug market.